Clinical Trials Logo

Filter by:
NCT ID: NCT06170944 Not yet recruiting - Stroke, Ischemic Clinical Trials

Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke

RICAS
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.

NCT ID: NCT06172933 Not yet recruiting - Middle Aged Clinical Trials

A Text- and Audio-based Intervention to Promote Physical Activity in Midlife

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This is a randomized, controlled pilot trial (N=30) to examine the feasibility, acceptability, and preliminary efficacy of the Move with Meaning program, an 8- week, text message- and audio-based intervention to promote physical activity in midlife adults.

NCT ID: NCT06173713 Not yet recruiting - Hip Osteoarthritis Clinical Trials

Emphasys Radiostereometric Analysis

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This study is designed as a prospective, multi-centre, non-randomized, non-controlled study. This study does not limit the procedures involved in the treatment of the subject as long as the protocol specified products are utilized. The primary objective is to establish the mean superior cup migration of the Emphasys Shell and the mean inferior stem migration of the Emphasys Stem using model-based RSA over the first two years post-implantation. Additionally, the data from this study will be compared to historical Pinnacle Acetabular Shell data obtained in study DSJ_2018_02.

NCT ID: NCT06174220 Not yet recruiting - Clinical trials for Arrhythmogenic Right Ventricular Cardiomyopathy

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

TaRGET
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.

NCT ID: NCT06174766 Not yet recruiting - Hypertension Clinical Trials

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension

NCT ID: NCT06176209 Not yet recruiting - Clinical trials for Neck Pain Following Traffic Accident

Validating a Brief Screening Tool With Biomarkers for Prediction of Chronic Post Traumatic Neck Pain

Start date: April 1, 2024
Phase:
Study type: Observational

Early screening of posttraumatic neck pain after accidents - A clinical prediction tool with biomarkers predicting chronic posttraumatic neck pain. The goal of this prospective cohort study is to develop a clinical prediction tool with biomarkers for early prediction of chronic posttraumatic neck pain. Aims: 1. validate and further develop an existing prediction and screening tool for post traumatic neck pain using biomarkers for stress (i.e. HRV). The investigators hypothesize that the addition of a HRV to the existing screening and prediction tool in the acute phase (i.e. < 72 hours) post-accident can contribute to better and earlier identification of high-risk patients who continue to experience moderate to high degree of impairment after 12 months (i.e. NDI >32%). 2. examine whether the health economic costs for the group that does not improve are greater after 12 months. The investigators hypothesize that the health economic costs for the group that does not improve are greater after 12 months (labour market attachment and health services) compared to those who improve (NDI score < 10% vs. > 32%). 3. evaluate the role of low HRV on the development of PTSD 3 month after the accident. the hypothesis is that low HRV is a predictor of the development of PTSD.3 month after an accident. 4. Evaluate whether PTSD mediates the association between low HRV and pain sensitization 3 months after the accident. The investigators hypothesize that the development of pain sensitivity 3 month after an accident is associated with low HRV and PTSD. Following inclusion participants will undergo evaluation of: Hart rate variability using Fristbeat Bodyguard II, neurologic screening, Cervical range of motion screening. At followup (1- and 3-months) participants will undergo evaluation of. Evaluation of cervical range of motion, Quantitative sensory testing (pressure pain threshold, cold pressor test followed by pressure pain threshold. Questionnaires: Acute self-reported stress (NRS), Expected improvement (0-100%), Pain (Short Form -McGill pain questionnaire) Neck disability index, Stress, anxiety and depression, post-traumatic stress disorder, Pain catastrophizing, Quality of life, Global rating of change, Self-reported sleep, Comorbidity, Physical Activity. At 6- and 12- month: Evaluation of heart rate variability and the questionnaires from 1- week and 3 months will be repeated.

NCT ID: NCT06181591 Not yet recruiting - Overactive Bladder Clinical Trials

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the efficacy of Hibero (Mirabegron) versus active control (Ditropan: Oxybutynin Chloride) in the treatment of pediatric subjects (5 to < 18 years of age) with overactive bladder. This study will further evaluate the safety of mirabegron in pediatric subjects with OAB after multiple dose adminstration.

NCT ID: NCT06181929 Not yet recruiting - Clinical trials for Health Risk Behaviors

A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This is a single-arm prospective pilot study in a single institution. The target accrual is 200 participants of Korean, female sex, never smoker status, and family history of lung cancer. The study will aim to enroll 200 participants in two years.

NCT ID: NCT06188910 Not yet recruiting - Anxiety Clinical Trials

Neurofeedback and Nomophobia in Young Adults

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Introduction: Given the growing increase in addiction to social networks and smartphone use in young people and its implications for health, it is necessary to investigate effective interventions for the appropriate use of these technologies and coping with possible signs of addiction. Objective: To evaluate the effect of an intervention based on neurofeedback techniques on anxiety and other disorders associated with problematic use of mobile phones and the internet in young adults. Methodology: Randomised controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will be young adults aged 18-30 years. A sample size of 36 participants has been estimated, 18 in each group to detect a difference of 3.9 points or more on the DASS-21 anxiety questionnaire. All participants will receive an educational workshop on the responsible use of new technologies and the promotion of healthy lifestyles. The IG, in addition to this educational workshop, will receive 20 neurofeedback sessions during 8 weeks, 2-3 sessions/week with the MUSE neurofeedback device. A baseline and 3-month post-intervention assessment will be conducted for both groups to study change variables related to smartphone addiction (Smartphone Addiction Scale-Short Version (SAS-SV)), nomophobia (Nomophobia Questionnaire (NMP-Q)), depression, anxiety and stress (Depression, Anxiety and Stress Scale 21-item (DASS-21)) and sleep quality.

NCT ID: NCT06189703 Not yet recruiting - ADHD Clinical Trials

tRNS Treatment for ADHD Symptoms

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.